Collineau L, Belloc C, Stärk K D C, Hémonic A, Postma M, Dewulf J, Chauvin C
SAFOSO AG, Bern, Liebefeld, Switzerland.
BIOEPAR, INRA, Oniris, Nantes, France.
Zoonoses Public Health. 2017 May;64(3):165-184. doi: 10.1111/zph.12298. Epub 2016 Sep 4.
An increasing variety of indicators of antimicrobial usage has become available in human and veterinary medicine, with no consensus on the most appropriate indicators to be used. The objective of this review is therefore to provide guidance on the selection of indicators, intended for those aiming to quantify antimicrobial usage based on sales, deliveries or reimbursement data. Depending on the study objective, different requirements apply to antimicrobial usage quantification in terms of resolution, comprehensiveness, stability over time, ability to assess exposure and comparability. If the aim is to monitor antimicrobial usage trends, it is crucial to use a robust quantification system that allows stability over time in terms of required data and provided output; to compare usage between different species or countries, comparability must be ensured between the different populations. If data are used for benchmarking, the system comprehensiveness is particularly crucial, while data collected to study the association between usage and resistance should express the exposure level and duration as a measurement of the exerted selection pressure. Antimicrobial usage is generally described as the number of technical units consumed normalized by the population at risk of being treated in a defined period. The technical units vary from number of packages to number of individuals treated daily by adding different levels of complexity such as daily dose or weight at treatment. These technical units are then related to a description of the population at risk, based either on biomass or number of individuals. Conventions and assumptions are needed for all of these calculation steps. However, there is a clear lack of standardization, resulting in poor transparency and comparability. By combining study requirements with available approaches to quantify antimicrobial usage, we provide suggestions on the most appropriate indicators and data sources to be used for a given study objective.
在人类医学和兽医学中,越来越多的抗菌药物使用指标可供使用,但对于最适宜使用的指标尚无共识。因此,本综述的目的是为指标的选择提供指导,面向那些旨在根据销售、交付或报销数据来量化抗菌药物使用情况的人员。根据研究目的,抗菌药物使用情况量化在分辨率、全面性、随时间的稳定性、评估暴露的能力和可比性方面有不同要求。如果目的是监测抗菌药物使用趋势,使用一个强大的量化系统至关重要,该系统在所需数据和提供的输出方面要随时间保持稳定;为了比较不同物种或国家之间的使用情况,必须确保不同人群之间具有可比性。如果数据用于基准测试,系统的全面性尤为关键,而收集用于研究使用情况与耐药性之间关联的数据应以暴露水平和持续时间来表示所施加的选择压力。抗菌药物使用情况通常被描述为在规定时期内,按有治疗风险的人群进行标准化的消耗技术单位数量。技术单位从包装数量到通过增加不同复杂程度(如每日剂量或治疗时的体重)来表示的每日治疗个体数量不等。然后,这些技术单位与基于生物量或个体数量的有风险人群描述相关。所有这些计算步骤都需要惯例和假设。然而,明显缺乏标准化,导致透明度和可比性较差。通过将研究要求与现有的抗菌药物使用情况量化方法相结合,我们针对给定的研究目的,就最适宜使用的指标和数据来源提供建议。